Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment.

Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Abstract Text:

After allogeneic stem cell transplantation (allo-SCT) some patients develop persistent anemia in association with an inadequate erythropoietin (Epo) secretion. We determined the frequency and risk factors for this complication and the response to treatment with erythropoiesis stimulating proteins (ESP). Of 83 evaluable allo-SCT patients, 63 (76%) developed persistent anemia at a median of 34 (range: 30-244) days after allo-SCT. Forty-one (49%) patients had anemia considered as primary, and in all of them inadequate serum Epo levels (median 43.3, range: 2.5-134, mU/mL) were found. A high creatinine level during the first month after allo-SCT was associated with primary anemia (relative risk [RR] 2.5, P = .01). Of the 41 patients, 35 received ESP. Transfusion independence and an Hb level higher than 10 g/dL was achieved in 29 of 30 (97%) evaluable patients. Median ferritin levels at the beginning and at the end of the ESP treatment was 1628 (range: 168-5208) and 805 (range: 14-7443) ng/mL, respectively (P = .04). In conclusion, anemia associated with impaired Epo secretion after allo-SCT is more frequent than usually recognized and it is associated to early postransplantation renal damage. This complication easily reverts with ESP, which seems to contribute to reduce iron overload.

Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Biology of blood and marrow transplantation : jour

VOLUME: 14

Page Numbers: 880-7

Journal Abbreviation: Biol. Blood Marrow Transplant.

ISSN: 1523-6536

DAY: 21

MONTH: Aug

YEAR: 2008

Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9600628

Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment.

AFFILIATION: Department of Hematology, Institute of Hematoncology, Hospital Clínic of Barcelona, Barcelona, Spain.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Biol Blood Marrow Transplant

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment Related Publications

• Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment.
• Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution.
• Central nervous system involvement in mantle cell lymphoma.
• Chronic lymphocytic leukemia: case-based session.
• Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia.
• Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
• Further progress in CLL therapy.
• Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome.
• Management of sleep apnea: concordance between nonreference and reference centers.
• New prognostic markers in CLL.
• New prognostic markers in chronic lymphocytic leukemia.
• Potential dermal exposure to deltamethrin and risk assessment for manual sprayers: Influence of crop type.
• [Autologous haematopoietic stem cell transplantation in POEMS syndrome: results in 4 cases.]
• [Clinical forms of the sympathetic temporomandibular syndrome of Costen-Abelló.]
• [Not Available.]
• [Not Available.]